Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12071195 | 0.92 | EPHX2 (0.56) | EPHX2KMT2AFABP5FABP7ABL1 | |
| SCHEMBL8366872 | 0.88 | EPHX2 (0.75) | EPHX2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL30094161 | 0.87 | EPHX2 (0.74) | EPHX2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL17151439 | 0.87 | EPHX2 (0.74) | EPHX2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL19683052 | 0.87 | EPHX2 (0.59) | EPHX2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL23212115 | 0.86 | EPHX2 (0.65) | EPHX2KMT2AFABP5FABP7CA1 | |
| SCHEMBL727842 | 0.86 | EPHX2 (0.62) | EPHX2KMT2AFABP5FABP7CA1 | |
| SCHEMBL31607197 | 0.86 | EPHX2 (0.65) | EPHX2KMT2AFABP5FABP7CA1 | |
| SCHEMBL14913645 | 0.86 | EPHX2 (0.64) | EPHX2KMT2AFABP5FABP7CASP3 | |
| SCHEMBL8366871 | 0.86 | EPHX2 (0.64) | EPHX2KMT2ACASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221992-A1 | DENDRITIC COMPOUNDS INCLUDING A CHELATING, FLUOROCHROME OR RECOGNITION AGENT, COMPOSITIONS INCLUDING SAME AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-08-04 | — | — | US | disclosed |
| US-20160221992-A1 | DENDRITIC COMPOUNDS INCLUDING A CHELATING, FLUOROCHROME OR RECOGNITION AGENT, COMPOSITIONS INCLUDING SAME AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS (FR) | 2016-08-04 | — | — | US | disclosed |
| US-9346799-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICALS AG (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2016-05-05 | — | — | US | disclosed |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | BASILEA PHARMACEUTICA AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-8901293-B2 | Useful combinations of monobactam antibiotics with beta-lactamase inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2014-12-02 | — | — | US | disclosed |
| WO-2014184503-A1 | DENDRITIC COMPOUNDS INCLUDING A CHELATING, FLUOROCHROME OR RECOGNITION AGENT, COMPOSITIONS INCLUDING SAME AND USES THEREOF | UNIVERSITE DE STRASBOURG (FR) | 2014-11-20 | — | — | WO | disclosed |
| US-8877961-B2 | Bridged monobactam intermediates | BASILEA PHARMACEUTICA AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20130274503-A1 | PROCESS FOR THE MANUFACTURE OF BRIDGED MONOBACTAM INTERMEDIATES | BASILEA PHARMACEUTICA AG (CH) | 2013-10-17 | — | — | US | disclosed |
| EP-2484680-B1 | Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2013-06-26 | — | — | EP | disclosed |
| EP-1965798-B1 | USEFUL MONOBACTAM ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2011-10-19 | — | — | EP | disclosed |
| US-20110178291-A1 | Process for the manufacture of bridged monobactam intermediates | Basilea Pharmacuetica AG | 2011-07-21 | — | — | US | disclosed |
| EP-2308874-A1 | Useful beta-lactamase inhibitors | Basilea Pharmaceutica AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2197881-A1 | PROCESS FOR THE MANUFACTURE OF BRIDGED MONOBACTAM INTERMEDIATES | Basilea Pharmaceutica AG (CH) | 2010-06-23 | — | — | EP | disclosed |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | BASILEA PHARMACEUTICA AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2009037229-A1 | PROCESS FOR THE MANUFACTURE OF BRIDGED MONOBACTAM INTERMEDIATES | BASILEA PHARMACEUTICA AG (CH) | 2009-03-26 | — | — | WO | disclosed |
| US-20040204348-A1 | Cyclic peptide ligands that target urokinase plasminogen activator receptor | THE ANGSTROM PHARMACEUTICALS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1144604-A1 | CYCLIC PEPTIDE LIGANDS THAT TARGET UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR, THEIR PHARMACEUTICAL COMPOSITIONS AND USE | Angstrom Pharmaceuticals, inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6277818-B1 | ANTITUMOR AGENT, ANTICANCER AGENTS | ANGSTROM PHARMACEUTICALS, INC. | 2001-08-21 | — | — | US | disclosed |
| WO-2000026353-A1 | CYCLIC PEPTIDE LIGANDS THAT TARGET UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR, THEIR PHARMACEUTICAL COMPOSITIONS AND USE | ANGSTROM PHARMACEUTICALS, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274503-A1 | PROCESS FOR THE MANUFACTURE OF BRIDGED MONOBACTAM INTERMEDIATES | COASY, ACMSD, BPGM | EPHX2 898/4885KMT2A 2978/4885FABP5 3132/4885 |
| US-20150031662-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | EPHX2 948/4885KMT2A 1169/4885FABP5 1978/4885 |
| US-20160221992-A1 | DENDRITIC COMPOUNDS INCLUDING A CHELATING, FLUOROCHROME OR RECOGNITION AGENT, COMPOSITIONS INCLUDING SAME AND USES THEREOF | MSR1, CD74, CD4 | EPHX2 1794/4885KMT2A 2340/4885FABP5 1927/4885 |
| US-20040204348-A1 | Cyclic peptide ligands that target urokinase plasminogen activator receptor | PLAUR, PLAU, PLG | EPHX2 2852/4885KMT2A 3792/4885FABP5 2014/4885 |
| US-20160122320-A1 | USEFUL COMBINATIONS OF MONOBACTAM ANTIBIOTICS WITH BETA-LACTAMASE INHIBITORS | MGAM, MGAM2, B2M | EPHX2 948/4885KMT2A 1169/4885FABP5 1978/4885 |
| US-20110178291-A1 | Process for the manufacture of bridged monobactam intermediates | C1S, CCNB1, C9 | EPHX2 559/4885KMT2A 2484/4885FABP5 4677/4885 |
| US-20100056478-A1 | Useful Combinations of Monobactam Antibiotics With Beta-Lactamase Inhibitors | MGAM, MGAM2, B2M | EPHX2 906/4885KMT2A 1199/4885FABP5 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.